Shikonin attenuates hyperhomocysteinemia-induced CD4
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Apolipoproteins E
/ deficiency
Atherosclerosis
/ drug therapy
CD4-Positive T-Lymphocytes
/ drug effects
Dose-Response Relationship, Drug
Female
Hyperhomocysteinemia
/ drug therapy
Inflammation
/ drug therapy
Injections, Intraperitoneal
Mice
Mice, Inbred C57BL
Mice, Knockout
Naphthoquinones
/ administration & dosage
ApoE−/− mice
CD4+ T cell
atherosclerosis
hyperhomocysteinemia
metabolic suppression
naphthoquinone
shikonin
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
17
06
2019
accepted:
06
09
2019
pubmed:
15
10
2019
medline:
2
10
2020
entrez:
15
10
2019
Statut:
ppublish
Résumé
T cell metabolic activation plays a crucial role in inflammation of atherosclerosis. Shikonin (SKN), a natural naphthoquinone with anti-inflammatory activity, has shown to exert cardioprotective effects, but the effect of SKN on atherosclerosis is unclear. In addition, SKN was found to inhibit glycolysis via targeting pyruvate kinase muscle isozyme 2 (PKM2). In the present study, we investigated the effects of SKN on hyperhomocysteinemia (HHcy)-accelerated atherosclerosis and T cell inflammatory activation in ApoE
Identifiants
pubmed: 31607752
doi: 10.1038/s41401-019-0308-7
pii: 10.1038/s41401-019-0308-7
pmc: PMC7468273
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Apolipoproteins E
0
Naphthoquinones
0
shikonin
3IK6592UBW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-55Références
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
doi: 10.1016/S0140-6736(12)61728-0
McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–9.
doi: 10.1038/nm0496-386
Guthikonda S, Haynes WG. Homocysteine as a novel risk factor for atherosclerosis. Curr Opin Cardiol. 1999;14:283–91.
doi: 10.1097/00001573-199907000-00002
Deng J, Lu S, Liu H, Liu B, Jiang C, Xu Q, et al. Homocysteine activates B cells via regulating PKM2-dependent metabolic reprogramming. J Immunol. 2017;198:170–83.
doi: 10.4049/jimmunol.1600613
Ma K, Lv S, Liu B, Liu Z, Luo Y, Kong W, et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice. Cardiovasc Res. 2013;97:349–59.
doi: 10.1093/cvr/cvs330
Andujar I, Rios JL, Giner RM, Recio MC. Pharmacological properties of shikonin - a review of literature since 2002. Planta Med. 2013;79:1685–97.
doi: 10.1055/s-0033-1350934
Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297–306.
doi: 10.1038/onc.2011.137
Yang L, Xie M, Yang M, Yu Y, Zhu S, Hou W, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014;5:4436.
doi: 10.1038/ncomms5436
Xie M, Yu Y, Kang R, Zhu S, Yang L, Zeng L, et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat Commun. 2016;7:13280.
doi: 10.1038/ncomms13280
Spyrelli ED, Kyriazou AV, Virgiliou C, Nakas A, Deda O, Papageorgiou VP, et al. Metabolic profiling study of shikonin’s cytotoxic activity in the Huh7 human hepatoma cell line. Mol Biosyst. 2017;13:841–51.
doi: 10.1039/C6MB00830E
Zhang X, Hu W, Wu F, Yuan X, Hu J. Shikonin inhibits TNF-alpha-induced growth and invasion of rat aortic vascular smooth muscle cells. Can J Physiol Pharmacol. 2015;93:615–24.
doi: 10.1139/cjpp-2014-0464
Lu S, Deng J, Liu H, Liu B, Yang J, Miao Y, et al. PKM2-dependent metabolic reprogramming in CD4(+) T cells is crucial for hyperhomocysteinemia-accelerated atherosclerosis. J Mol Med (Berl). 2018;96:585–600.
doi: 10.1007/s00109-018-1645-6
Dai XY, Cai Y, Sun W, Ding Y, Wang W, Kong W, et al. Intermedin inhibits macrophage foam-cell formation via tristetraprolin-mediated decay of CD36 mRNA. Cardiovasc Res. 2014;101:297–305.
doi: 10.1093/cvr/cvt254
Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181–6.
doi: 10.1038/nature06667
Feng J, Zhang Z, Kong W, Liu B, Xu Q, Wang X. Regulatory T cells ameliorate hyperhomocysteinaemia-accelerated atherosclerosis in apoE
doi: 10.1093/cvr/cvp182
Liu Z, Luo H, Zhang L, Huang Y, Liu B, Ma K, et al. Hyperhomocysteinemia exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. Circ Res. 2012;111:1261–73.
doi: 10.1161/CIRCRESAHA.112.270520
Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12–26.
doi: 10.1111/j.1600-065X.2009.00770.x
Ivashkiv LB. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545–58.
doi: 10.1038/s41577-018-0029-z
Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 2015;36:81–91.
doi: 10.1016/j.it.2014.12.005
Yang J, Wang Z, Chen DL. Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress. Biomed Pharmacother. 2017;93:1343–57.
doi: 10.1016/j.biopha.2017.06.086
Han T, Zhang G, Yan D, Yang H, Ma T, Ye Z. Modulation of plasminogen activator inhibitor-1 (PAI-1) by the naphthoquinone shikonin. Fitoterapia. 2016;113:117–22.
doi: 10.1016/j.fitote.2016.07.010
Yoshida LS, Kawada T, Irie K, Yuda Y, Himi T, Ikemoto F, et al. Shikonin directly inhibits nitric oxide synthases: possible targets that affect thoracic aorta relaxation response and nitric oxide release from RAW 264.7 macrophages. J Pharmacol Sci. 2010;112:343–51.
doi: 10.1254/jphs.09340FP
Dai Q, Fang J, Zhang FS. Dual role of shikonin in early and late stages of collagen type II arthritis. Mol Biol Rep. 2009;36:1597–604.
doi: 10.1007/s11033-008-9356-7
Lee CC, Wang CN, Lai YT, Kang JJ, Liao JW, Chiang BL, et al. Shikonin inhibits maturation of bone marrow-derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthma. Br J Pharmacol. 2010;161:1496–511.
doi: 10.1111/j.1476-5381.2010.00972.x
Lee CC, Kang JJ, Chiang BL, Wang CN, Cheng YW. Shikonin inhibited mitogen-activated IL-4 and IL-5 production on EL-4 cells through downregulation of GATA-3 and c-Maf induction. Life Sci. 2011;89:364–70.
doi: 10.1016/j.lfs.2011.07.002
Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297–329.
doi: 10.1146/annurev.pathol.1.110304.100100
O’Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol. 2015;36:71–80.
doi: 10.1016/j.it.2014.12.004
Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342:1242454.
doi: 10.1126/science.1242454
Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014;20:1327–33.
doi: 10.1038/nm.3704
Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–72.
doi: 10.1038/42408
Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017;35:7–14.
doi: 10.1016/j.cytogfr.2017.04.003
Sarrazy V, Viaud M, Westerterp M, Ivanov S, Giorgetti-Peraldi S, Guinamard R, et al. Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE
doi: 10.1161/CIRCRESAHA.115.307599
Shirai T, Nazarewicz RR, Wallis BB, Yanes RE, Watanabe R, Hilhorst M, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med. 2016;213:337–54.
doi: 10.1084/jem.20150900